The Latin America, Middle East and Africa Immune Checkpoint Inhibitors Market would witness market growth of 18.7% CAGR during the forecast period (2021-2027).
Immunotherapy, in contrast to traditional cancer therapies like radiotherapy and chemotherapy, is a cutting-edge treatment that dynamically regulates the immune system to combat cancer cells in many targets and directions. Most of the effects will be considerably amplified when used in conjunction with conventional anti-tumor therapy or numerous immune-checkpoint inhibitors (ICIs), but the exact circumstance would need to be researched further. Immune checkpoint inhibitors are increasingly becoming more accessible for people all over the word. The study of similar anti-tumor medications is amid progress, and the market &use of these drugs are flourishing.
Alternative cancer treatment techniques are now actively involved in slowing cancer's progression. Precision medicines are another name for these treatments. Alternative cancer therapy has recently gotten a lot of attention in the industry since these therapies use complementary and alternative techniques and approaches to prevent and treat cancer at an earlier stage.
São Paulo has been a pioneer in the use of ICIs in Brazil since 2012 when research trials were supported by clinical practice. An increase in the spending capacities of people in countries like Argentina would allow the penetration of immune checkpoint inhibitors across the region. Moreover, Breast, bladder, and liver cancers are the most common malignancies in Northern Africa; prostate, lung, and colorectal cancers are the most common cancers in Southern Africa; and esophageal and cervical cancers are the most common cancers in East Africa. Prostate cancer and cervical cancer death rates have risen in Southern Africa.
According to the National Library of Medicine, population expansion and aging would result in a 70% increase in new cancer occurrences by 2030. This persistent condition has coexisted in Africa with newly found communicable diseases like Malaria, Ebola, AIDS, and COVID-19.
The Brazil market dominated the LAMEA Immune Checkpoint Inhibitors Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $658.5 million by 2027. The Argentina market is exhibiting a CAGR of 19.3% during (2021 - 2027). Additionally, The UAE market would showcase a CAGR of 18.4% during (2021 - 2027).
Based on Application, the market is segmented into Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others. Based on Type, the market is segmented into PD-1 Inhibitor, PD-L1 Inhibitor, and CTLA-4 Inhibitor. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Immune Checkpoint Inhibitors Market is Predict to reach $75.9 Billion by 2027, at a CAGR of 16.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Beigene Ltd., Shanghai Junshi Biosciences Co., Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Merck Group (Merck Sharp & Dohme Corp.), Sanofi S.A., Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Lung Cancer
- Bladder Cancer
- Melanoma
- Hodgkin lymphoma
- Others
By Type
- PD-1 Inhibitor
- PD-L1 Inhibitor
- CTLA-4 Inhibitor
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Beigene Ltd.
- Shanghai Junshi Biosciences Co., Ltd.
- Bristol Myers Squibb Company
- GlaxoSmithKline PLC
- Eli Lilly and Company
- Merck Group (Merck Sharp & Dohme Corp.)
- Sanofi S.A.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Immune Checkpoint Inhibitors Market, by Application
1.4.2 LAMEA Immune Checkpoint Inhibitors Market, by Type
1.4.3 LAMEA Immune Checkpoint Inhibitors Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, May – 2021, Dec) Leading Players
Chapter 4. LAMEA Immune Checkpoint Inhibitors Market by Application
4.1 LAMEA Lung Cancer Market by Country
4.2 LAMEA Bladder Cancer Market by Country
4.3 LAMEA Melanoma Market by Country
4.4 LAMEA Hodgkin lymphoma Market by Country
4.5 LAMEA Other Application Market by Country
Chapter 5. LAMEA Immune Checkpoint Inhibitors Market by Type
5.1 LAMEA PD-1 Inhibitor Market by Country
5.2 LAMEA PD-L1 Inhibitor Market by Country
5.3 LAMEA CTLA-4 Inhibitor Market by Country
Chapter 6. LAMEA Immune Checkpoint Inhibitors Market by Country
6.1 Brazil Immune Checkpoint Inhibitors Market
6.1.1 Brazil Immune Checkpoint Inhibitors Market by Application
6.1.2 Brazil Immune Checkpoint Inhibitors Market by Type
6.2 Argentina Immune Checkpoint Inhibitors Market
6.2.1 Argentina Immune Checkpoint Inhibitors Market by Application
6.2.2 Argentina Immune Checkpoint Inhibitors Market by Type
6.3 UAE Immune Checkpoint Inhibitors Market
6.3.1 UAE Immune Checkpoint Inhibitors Market by Application
6.3.2 UAE Immune Checkpoint Inhibitors Market by Type
6.4 Saudi Arabia Immune Checkpoint Inhibitors Market
6.4.1 Saudi Arabia Immune Checkpoint Inhibitors Market by Application
6.4.2 Saudi Arabia Immune Checkpoint Inhibitors Market by Type
6.5 South Africa Immune Checkpoint Inhibitors Market
6.5.1 South Africa Immune Checkpoint Inhibitors Market by Application
6.5.2 South Africa Immune Checkpoint Inhibitors Market by Type
6.6 Nigeria Immune Checkpoint Inhibitors Market
6.6.1 Nigeria Immune Checkpoint Inhibitors Market by Application
6.6.2 Nigeria Immune Checkpoint Inhibitors Market by Type
6.7 Rest of LAMEA Immune Checkpoint Inhibitors Market
6.7.1 Rest of LAMEA Immune Checkpoint Inhibitors Market by Application
6.7.2 Rest of LAMEA Immune Checkpoint Inhibitors Market by Type
Chapter 7. Company Profiles
7.1 AstraZeneca PLC
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Approvals and Trials:
7.2 Beigene Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 Shanghai Junshi Biosciences Co., Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.4 Bristol Myers Squibb Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 GlaxoSmithKline PLC (GSK)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Eli Lilly and Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.7 Merck Group (Merck Sharp & Dohme Corp.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Sanofi S.A.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.8.5.2 Approvals and Trials:
7.8.5.3 Acquisition and Mergers:
7.9 Merck & Co., Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals and Trials:
7.10. F. Hoffmann-La Roche Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Partnerships, Collaborations and Agreements:
7.10.5.2 Approvals and Trials:
TABLE 1 LAMEA Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 2 LAMEA Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Immune Checkpoint Inhibitors Market
TABLE 4 Acquisition and Mergers– Immune Checkpoint Inhibitors Market
TABLE 5 Approvals and Trials– Immune Checkpoint Inhibitors Market
TABLE 6 LAMEA Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 7 LAMEA Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 8 LAMEA Lung Cancer Market by Country, 2017 - 2020, USD Million
TABLE 9 LAMEA Lung Cancer Market by Country, 2021 - 2027, USD Million
TABLE 10 LAMEA Bladder Cancer Market by Country, 2017 - 2020, USD Million
TABLE 11 LAMEA Bladder Cancer Market by Country, 2021 - 2027, USD Million
TABLE 12 LAMEA Melanoma Market by Country, 2017 - 2020, USD Million
TABLE 13 LAMEA Melanoma Market by Country, 2021 - 2027, USD Million
TABLE 14 LAMEA Hodgkin lymphoma Market by Country, 2017 - 2020, USD Million
TABLE 15 LAMEA Hodgkin lymphoma Market by Country, 2021 - 2027, USD Million
TABLE 16 LAMEA Other Application Market by Country, 2017 - 2020, USD Million
TABLE 17 LAMEA Other Application Market by Country, 2021 - 2027, USD Million
TABLE 18 LAMEA Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 19 LAMEA Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 20 LAMEA PD-1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 21 LAMEA PD-1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 22 LAMEA PD-L1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 23 LAMEA PD-L1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 24 LAMEA CTLA-4 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 25 LAMEA CTLA-4 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 26 LAMEA Immune Checkpoint Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 27 LAMEA Immune Checkpoint Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 28 Brazil Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 29 Brazil Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 30 Brazil Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 31 Brazil Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 32 Brazil Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 33 Brazil Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 34 Argentina Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 35 Argentina Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 36 Argentina Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 37 Argentina Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 38 Argentina Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 39 Argentina Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 40 UAE Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 41 UAE Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 42 UAE Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 43 UAE Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 44 UAE Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 45 UAE Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 46 Saudi Arabia Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 47 Saudi Arabia Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 48 Saudi Arabia Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 49 Saudi Arabia Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 50 Saudi Arabia Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 51 Saudi Arabia Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 52 South Africa Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 53 South Africa Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 54 South Africa Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 55 South Africa Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 56 South Africa Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 57 South Africa Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 58 Nigeria Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 59 Nigeria Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 60 Nigeria Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 61 Nigeria Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 62 Nigeria Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 63 Nigeria Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 64 Rest of LAMEA Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 65 Rest of LAMEA Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 66 Rest of LAMEA Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 67 Rest of LAMEA Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 68 Rest of LAMEA Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 69 Rest of LAMEA Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 70 KEY INFORMATION – ASTRAZENECA PLC
TABLE 71 KEY INFORMATION – BEIGENE LTD.
TABLE 72 KEY INFORMATION – SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
TABLE 73 KEY INFORMATION – BRISTOL MYERS SQUIBB COMPANY
TABLE 74 KEY INFORMATION – GLAXOSMITHKLINE PLC
TABLE 75 KEY INFORMATION – ELI LILLY AND COMPANY
TABLE 76 KEY INFORMATION – MERCK GROUP
TABLE 77 KEY INFORMATION – SANOFI S.A.
TABLE 78 KEY INFORMATION - MERCK & CO., INC.
TABLE 79 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 4 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, May – 2021, Dec) Leading Players
FIG 5 Recent strategies and developments: Sanofi s.a.